NeoStem falls, author questions AMR-001 after study results

NeoStem (NBS -11.1%) started the day in positive territory but quickly faded into the red and is now down double-digits.

It looks likely that an article by SA contributor Probio Invest is weighing on the shares.

Probio says a study that showed autologous stem cells did not boost heart function "clearly does not bode well for NBS' AMR-001."

Comments (4)
  • brewbob47
    , contributor
    Comments (29) | Send Message
    The author with the pseudonym should not have made the statement "clearly does not bode well for NBS' AMR-001." That, to me, is tantamount to stock manipulation.


    His short foray into the SSH treatment didn't really provide enough information for the investor or trader to make an informed decision.


    I realize he mentioned that he was long SSH in his disclaimer, but that's meaningless if his intention was to line his own pockets with cheap shares of NBS or increase the value of his SSH. Or both.


    If Cramer could manipulate the stocks he had in his hedge fund, it's certainly plausible that the SA authors are doing the same thing.
    16 Sep 2013, 02:21 PM Reply Like
  • Sammyboy12
    , contributor
    Comments (313) | Send Message
    This is GREAT! What a chance to add to existing holdings.
    16 Sep 2013, 02:54 PM Reply Like
  • OverSouled
    , contributor
    Comments (282) | Send Message
    The study showed extremely positive biological results for repair of damaged heart tissue through stem cell therapy. The lack of functional improvement remains to be explained but the study demonstrated that stem cells did what they were expected to do. The negative spin of the report contrasts with the more balanced view taken by the researchers. Long NBS and considering picking up SSH as well - to me, the combined result of the two approaches sounds extremely promising.
    16 Sep 2013, 03:21 PM Reply Like
  • garyd4324
    , contributor
    Comment (1) | Send Message
    Probio is undoubtedly talking about a study that was done in Nov. of 2012. This has nothing to do with the study done on this research but everyone jumped up and ran. This stock dropped over $1 a share. I can assure you that you will not see this stock go up more than 50 cents. Everyone of those day traders who buy this stock low will be jumping on their profit the minute this stock goes back up. Within the next 2 years you're going to see major changes in the stock market. Companies like this need this money for research. If they can't depend on the money they get from their shareholders to be there when they need it then they're going to have to get it somewhere else. The stock market was never set up to be used as a casino and that's exactly what's happening today.
    16 Sep 2013, 08:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs